Industry Wire 241

January 24, 2025 Viktor Zarev 0 min read
  1. UnitedHealthcare taps Tim Noel as new CEO.
  2. Google spinoff starting first clinical trials for AI-designed drugs.
  3. Trump executive order would end funding for gain-of-function research.
  4. Providence realigns executive team: 12 things to know.
  5. Hospitals say they won’t turn patients away amid immigration debate.
  6. HHS halts external communications.
  7. PA-based Main Line Health eliminates 200 administrative / IT positions.
  8. Geisinger names chief marketing officer.
  9. CMS to appeal decision to recalculate UnitedHealthcare’s MA star ratings.
  10. Cleveland Clinic unveils new primary care model in Florida.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals May 7, 2026

Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026

The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.

Cardiovascular Disease May 4, 2026

The True Cause of Sudden Cardiac Death May 4, 2026

It’s not often that a pair of studies completely challenges our assumptions in cardiology, but new data presented at HRS 2026 suggests myocardial infarction might not be […]

Cardiology April 30, 2026

Cardiac Wire’s Top Six of HRS 2026 April 30, 2026

The Heart Rhythm Society's Annual Meeting for 2026 electrified Chicago with talks of the latest EP tech, rhythm management debates, and insights into where remote patient monitoring is headed. Here are Cardiac Wire’s top-six takeaways from electrophysiology’s biggest weekend of the year.